Cognitive problems occur in asymptomatic gene carriers of Huntington's disease (HD), and mouse models of the disease exhibit impaired learning and substantial deficits in the cytoskeletal changes that stabilize long-term potentiation (LTP). The latter effects may be related to the decreased production of brainderived neurotrophic factor (BDNF) associated with the HD mutation. This study asked whether up-regulating endogenous BDNF levels with an ampakine, a positive modulator of AMPA-type glutamate receptors, rescues plasticity and reduces learning problems in HD (CAG140) mice. Twice-daily injections of a short half-life ampakine normalized BDNF levels, activity-driven actin polymerization in dendritic spines, and LTP stabilization in 8-week-old mutants. Comparable results were obtained in 16-week-old HD mice with more severe LTP deficits. Ampakine treatments had no measurable effect on the decreased locomotor activity observed in the mutants but offset their impairments in long-term memory. Given that ampakines are well tolerated in clinical trials and were effective in this study after brief exposures, these results suggest a novel strategy for chronic treatment of the cognitive difficulties that occur in the early stages of HD.
H
untington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by a mutation involving the trinucleotide CAG in the huntingtin gene (1, 2) . Although severe motor impairments characterize the disease, cognitive and memory deficits are also present and often appear in advance of other symptoms (3) (4) (5) (6) . Impaired learning that occurs before or concurrent with motor dysfunction or neuron loss has been described for HD mouse models (7) (8) (9) as have deficits in hippocampal long-term potentiation (LTP) (10) (11) (12) (13) , a form of synaptic plasticity widely regarded as a neurobiological substrate for memory. Understanding why LTP is severely impaired in HD mice could explain the cognitive dysfunction seen in patients with the disease.
Our recent investigations into HD-associated plasticity deficits established that actin polymerization in dendritic spines, which normally stabilizes LTP (14, 15) , is defective in HD knockin mice and most likely explains the rapid decay of potentiation (11) . Pertinent to this finding, both HD mice and patients have reduced forebrain levels of brain-derived neurotrophic factor (BDNF) and its TrkB receptor (16, 17) . BDNF is a releasable neurotrophin that promotes activity-driven actin polymerization in dendritic spines (15, 18) and potently facilitates LTP induction by theta burst stimulation (TBS; refs. 19 and 20) . Thus, an HD-related failure in BDNF signaling could remove an essential element of the system that modifies the spine cytoskeleton, thereby disrupting the stable synaptic changes needed to encode memory. Accordingly, applying low concentrations of BDNF fully restored TBS-induced actin polymerization and LTP in hippocampal slices prepared from HD mice (11).
The above results suggest a BDNF-based therapeutic strategy for treating HD-associated memory impairments. Although methods for direct treatment with the neurotrophin are not yet practical, numerous experimental manipulations exist that elevate its production in brain (21) . For the present experiments, we chose daily treatments with an ampakine, one of a class of drugs that, via allosteric modulation of AMPA-type glutamate receptors, increases excitatory transmission in the forebrain and thereby up-regulates BDNF expression (22) . Because BDNF protein has a long half-life, relatively brief periods of enhanced transmission may be used to produce lasting increases in BDNF levels (23) . Here, we tested whether a short half-life ampakine elevates BDNF in HD knockin mice and whether such an effect rescues both TBS-induced actin polymerization in dendritic spines and stable LTP. Ensuing experiments tested whether ampakine treatments alleviate HD-associated memory deficits in a paradigm that emphasizes the unsupervised nature of learning in complex environments.
Results
Exogenous BDNF Promotes LTP in CAG140 Mice. Field excitatory postsynaptic potentials (fEPSPs) were not detectably different in field CA1 of hippocampal slices prepared from 8-week-old CAG140 and wild-type (WT) mice with regard to amplitude or waveform (Fig. S1 A) . Paired pulse facilitation, a test for presynaptic neurotransmitter mobilization, was also comparable between genotypes (50-ms delay, for WT: 61 Ϯ 10%, n ϭ 10; for CAG140: 56 Ϯ 4%, n ϭ 7; means Ϯ SEM; P Ͼ 0.05) as were input/output curves for the Schaffer-commissural projections (Fig. S1B) . LTP deficits were present in 8-week-old CAG140 mice, as in other HD models (11) (12) (13) : mean percentage potentiation for the last 5 min of a 40-min recording session was 52.2 Ϯ 9.5% (Ϯ SEM) above baseline in WT slices (n ϭ 17) and 29.6 Ϯ 5.6% for a set of 24 CAG140 slices (P ϭ 0.036; 2-tailed t test). Using 1 SD below the mean of WT potentiation as a criterion for a failure to potentiate, we found that LTP did not occur in 38% of HD slices vs. 6% of WTs (P ϭ 0.028, 2-tailed Fisher's exact test). A 40-min infusion of BDNF (2 nM) moved LTP in CAG140 slices (72.0 Ϯ 10.6%;) into the WT range (P ϭ 0.37 vs. WTs), whereas boiled BDNF had no detectable effect (24.2 Ϯ 9.7%; P ϭ 0.012, BDNF vs. boiled BDNF) (Fig. 1) .
Up-Regulating Endogenous BDNF Restores LTP in CAG140 Mice. Ampakine CX929 (5 mg/kg) or vehicle was injected twice daily to handled 8-week-old CAG140 and WT mice for 4 days; mice were killed 18 h after the last injection, which is well after the drug's half-life of Ϸ15 min (Tables S1 and S2 ). Western blots of hippocampal homogenates detected bands corresponding in weight to pro BDNF and mature (m) BDNF and partially digested fragments of the former ( Fig. 2A) . Levels of the 14-to 15-kDa mBDNF were lower by Ϸ30% in vehicle-treated CAG140 mice relative to WTs ( Fig. 2B ; n ϭ 8-9 per group; P Ͻ 0.001, one-tailed t test), a deficit comparable with that found in other HD strains (11) . CX929-treated CAG140 mice had higher mBDNF levels (P Ͻ 0.01 vs. vehicle) that nearly matched those of WTs.
Baseline transmission, as assessed by input/output curves ( Fig.  S1C ) and the amplitude and waveform of fEPSPs, was not detectably altered in hippocampal slices from CX929-treated mice. Paired pulse facilitation also appeared normal (50-ms delay: 49 Ϯ 17% for CAG140 ϩ ampakine; 56 Ϯ 25% for WT ϩ ampakine; P Ͼ 0.05). However, LTP was more robust in slices from CAG140 mice treated with CX929 (63.3 Ϯ 10.1% potentiation at 40 min, n ϭ 13) than those given vehicle (31.5 Ϯ 6.8%, n ϭ 18; P ϭ 0.01; Fig. 3A ) and potentiation stabilized at WT levels.
LTP Deficits in CAG140 Mice Are Progressive. Sixteen-week-old CAG140 mice were given CX929 or vehicle injections following the paradigm used above. LTP was more severely depressed in the older vehicle-treated CAG140 mice (P ϭ 0.024, for 8-vs. 16-week-old CAG140 mice; Fig. 3B ) and decayed to baseline by 40 min after TBS. Despite the severity of the deficit in the 16-week-old mice, CX929 treatments restored LTP to WT levels; percentage potentiation at 40 min post-TBS was 46.4 Ϯ 7.3% (n ϭ 7) in WT, 2.4 Ϯ 6.2% (n ϭ 7) for vehicle-treated CAG140 mice (P ϭ 0.002 vs. WTs), and 50.6 Ϯ 13.5% (n ϭ 14) for CX929-treated CAG140 mice (P ϭ 0.007 vs. CAG140 vehicle slices) (Fig. 3C ). Comparable differences between the groups were evident at 30 min post-TBS (Fig. 3C ).
Up-Regulating Endogenous BDNF Restores Activity-Driven Actin Polymerization. Actin polymerization in dendritic spines, an essential event for stabilizing LTP (14, 15) , is substantially impaired in HD mouse models (11) . Accordingly, we tested whether reversal of this cytoskeletal defect could account for the rescue of LTP by CX929. F-actin was labeled with phalloidin after physiological testing (14) . WT slices that received only baseline stimulation had few densely labeled spines in the dendritic region innervated by stimulated fibers; this value was markedly increased by TBS (46.5 Ϯ 3.9 spines per 550 m 2 ; n ϭ 8). The corresponding number for slices prepared from vehicle-treated CAG140 mice was 8.5 Ϯ 0.7 spines per 550 m 2 (n ϭ 14; P ϭ group mean Ϯ SEM raw band density values for n Ն 8 per group). CAG140 mice treated with CX929 had higher mBDNF levels than those given vehicle (ϩ, P ϭ 0.008). Similar results were obtained when the values were normalized to those for the tubulin immunobands. 0.0002 versus WT; Fig. 4 ), confirming defective TBS-induced actin polymerization in the mutants (11) . In vivo ampakine treatments corrected the activity-induced spine F-actin deficit (Fig. 4A Lower) . Mean numbers of labeled spines in slices from CAG140 mice given CX929 (41.0 Ϯ 4.4 spines per 550 m 2 ; n ϭ 8) were not reliably different from WT values (P ϭ 0.75) and were substantially greater than counts in vehicle-treated mutants (P ϭ 0.002; Fig. 4B ).
Effects of Chronic Ampakine Treatment on Behavior of CAG140 Mice.
Memory and other variables were examined in an unsupervised learning task involving a complex environment. There is a large amount of literature linking the hippocampus to this type of activity, and unsupervised paradigms provide multiple dimensions across which to detect behavioral differences (24) . The distance traveled by 16-week-old CAG140 mice (n ϭ 19) was reduced relative to WT (Ϫ35 Ϯ 6% on test day 1; P Ͻ 0.0001, n ϭ 17, 2-tailed t test; Fig. 5A ). The decrease in the mutants was traced to (i) a greater decrease in the frequency of movements between the first and last 20 min of testing (P ϭ 0.01 for day 1; Fig. 5B ) and (ii) slower movements (10.9 Ϯ 1.4 mm/s vs. 13.5 Ϯ 1.9 mm/s for WT, P ϭ 0.00003; Fig. 5C ). Ampakine treatment (n ϭ 17) did not measurably change the distance traveled or movement frequency, speed, or duration in CAG140 mice (Fig.  5 A-D) .
The 3 groups did not detectably differ in regard to the spatial allocation of their activities, total locomotion time, or time spent moving by the objects on testing days 2 (Fig. S2) or 3, indicating that exploratory activity was not significantly affected by decreased locomotion in the mutants. Changes in the distribution of movement time across arena subdomains from day 2 to 3 (unaltered complex environment) were used as a measure of how experience modified behavior. WT mice showed a small, but highly consistent (P Ͻ 0.0001, ANOVA) shift in behavior between days 2 and 3 that involved decreases in time in the ''refuge'' (P Ͻ 0.0001, paired 2-tailed t test) and increases in the open field (P ϭ 0.05) and corners (P ϭ 0.01; Fig. 5E Top) . Vehicle-treated CAG140 mice were extremely variable with regard to across-day shifts in their exploratory activities: none of the changes in time spent in specific zones approached statistical significance (P Ͼ 0.8 for all 5 zones) nor did the overall pattern of behavior adjustments (P Ͼ 0.85, ANOVA; Fig. 5E Middle) . Indeed, the majority of vehicle-treated mutants (11 of 19) had day 2 to day 3 shift-scores for the refuge that were Ͼ1 SD removed from the WT mean (P ϭ 0.04, WT vs. vehicle-treated CAG140 mice, Fishers Exact Test, 2-tailed).
In striking contrast, CAG140 mice that received ampakine treatments were as consistent in their between-day changes as were WT mice (Fig. 5E Bottom) . The changes for each zone were statistically significant (P ϭ 0.05 to 0.0001, for day 2 vs. 3) as was the overall pattern of changes (P Ͻ 0.0001). Further analysis confirmed that CX929 treatment eliminated the day 2 to day 3 shift-score outliers as were present in the CAG140 ϩ vehicle group (P ϭ 0.04; 2 ϫ 3 contingency table analysis: 2 ϭ 6.26, df ϭ 2, P ϭ 0.04).
Chronic CX929 Treatment Reduces Long-Term Memory Deficits in CAG140 Mice. Long-term memory was also assessed by using novel object recognition (1 of the 2 identical objects present in the test arena on days 2 and 3 was replaced with an unfamiliar object before test day 4). Time spent at the novel (switch) object location on days 3 and 4 was expressed as a fraction of time spent in both locations; the percentage increase in these ratios (relative to day 4) provided a ''novelty detection index.'' Five of 53 mice, distributed across the 3 groups, were excluded from the analysis because they were markedly asymmetrical in their object exploration time on day 3 (Ͻ25% or Ͼ75% time at the switch location). WT mice increased the ratio of time spent at the switch location from 55 Ϯ 15% on day 3 to 74 Ϯ 9% on day 4; the Ϸ30% increase in relative time with the novel object was highly significant (P ϭ 0.00001).
The 2 experimental predictions for the study were that (i) vehicle-treated CAG140 mice would have a smaller than normal increase in their novelty detection indices and (ii) CX929 would improve these scores. The results summarized in Fig. 6 confirm these predictions. The ampakine did not measurably affect object exploration time on day 3 (P ϭ 0.40) but improved the novelty detection index. The novelty detection index for vehicletreated CAG140 mice (10 Ϯ 26%) was smaller than that for WT mice (27 Ϯ 17%) and ampakine-treated CAG140 mice (28 Ϯ 11%; P ϭ 0.02 and P ϭ 0.01 for vehicle-treated CAG140 mice vs. WT and CX929-treated CAG140 mice, respectively); the latter 2 groups were indistinguishable. One-third of the vehicletreated CAG140 mice did not show an increase in their novelty indices, whereas all of the WT and ampakine-treated CAG140 mice did (P ϭ 0.021 for each comparison, Fisher's Exact Test). These results again suggest that the HD mutation severely affected the behavior of a subpopulation of the 16-week-old CAG140 mice and that this group benefited from ampakine treatment. 
Discussion
The impaired BDNF expression reported for HD patients is a logical contributor to memory and cognitive problems associated with the disease. BDNF release and signaling are essential for inducing stable potentiation evoked by naturalistic theta stimulation (15) , and infusions of the neurotrophin offset LTP deficits in HD knockin mice (11) . These points suggest that normalizing BDNF expression could have positive effects on cognitive problems found in presymptomatic carriers of the HD mutation. The present studies provided a test of this idea.
Twice-daily treatments with a short half-life ampakine restored BDNF levels in CAG140 mice to WT values (as evaluated 1 day after the last ampakine treatment) and was accompanied by a return of normal-appearing LTP stabilization. The rescue was selective in that synaptic responses in slices from ampakinetreated CAG140 mice did not detectably differ from those given vehicle for several physiological measures, including the initial expression of potentiation. The ampakine results were seen in slices from young adult CAG140 mice in which the LTP deficit was moderate and in somewhat older mice with more pronounced impairments.
Plausible links exist between up-regulating BDNF and recovery of stable LTP. Stabilization depends on changes in the spine cytoskeleton (14) that are positively modulated by BDNF (15) . We previously reported that HD knockin mice have less activitydriven actin polymerization in dendritic spines than WTs, and that this impairment is eliminated by applying BDNF (11) . The present study used an intermittent ampakine treatment regimen (25) to demonstrate that up-regulating endogenous BDNF expression with CX929 has the same restorative effects on TBSdriven actin polymerization as does exogenous BDNF. These results are consistent with a model in which reduced BDNF expression in the mutants causes lower than normal BDNF release during theta stimulation and a resultant failure to activate signaling cascades needed to remodel the spine actin cytoskeleton. Ampakine treatment eliminated the deficit in BDNF expression, and thereby restored structural changes underlying the stabilization of LTP.
The behavioral consequences of the above neurobiological effects were tested by using exploration of a complex environment that allowed simultaneous measures of several types of activities. Total locomotor activity (i.e., distance moved) was significantly reduced in CAG140 mice largely because they initiated fewer movements and traveled with slower velocity. Neither movement variable was measurably affected by CX929. exploratory activity for vehicle-treated CAG140 mice were variable and did not reach statistical significance (P Ͼ 0.8 for all 5 zones). (Bottom) However, CAG140 mice given CX929 were as consistent in their between-day changes as were WT mice (ϩ, P Յ 0.05 to 0.0001 for all 5 regions, 2-tailed t tests). P, porch; Ob, both objects. Fig. 6 . Ampakine CX929 reverses a long-term memory deficit in CAG140 mice. Novel object recognition was assessed by replacing 1 of 2 identical objects present on day 3 with an unfamiliar object on day 4. The time spent in the switch (new object) location was expressed as a fraction of time spent in both locations; the percentage increase (relative to day 4 values) in the day 3 to day 4 ratios was used as a novelty detection index. This index was smaller in vehicle-treated CAG140 mice (10 Ϯ 26%; mean Ϯ SD) than in WT mice (27 Ϯ 17%; P ϭ 0.02) and ampakine-treated CAG140 mice (28 Ϯ 11%; P ϭ 0.01).
Behavioral testing was initiated after 4 days of drug treatment; it will be of interest to determine whether longer periods of BDNF up-regulation affect motor performance. The CAG140 mice spent similar amounts of time exploring the refuge, corners, and open field as did WT mice. This finding suggests that the HD mutation, at 16 weeks of age, does not substantially affect anxiety or other psychological variables that could influence exploration.
Initial tests for memory disturbances in CAG140 mice assessed behavioral changes in an unchanged environment between 2 consecutive testing days. WT mice exhibited a modest, but consistent, shift in activity between days that was dominated by a sizeable decrease in time spent in the refuge. CAG140 mice were extremely variable regarding behavioral shifts across days and, accordingly, there were no statistically meaningful changes in movement within any of the environmental zones. This result suggests that either learning is impaired or long-term memory has a more variable influence on behavior in CAG140 mice than in WT. Ampakine administration eliminated the WT vs. mutant differences and, if anything, exaggerated the pattern of acrossday changes in the former group.
Additional tests of ampakine effects on long-term memory in CAG140 mice used a novel object recognition test. WT mice showed marked increases in the proportion of time spent with a novel object in tests performed 24 h after their last exposure to familiar cues. This measure of long-term memory was substantially reduced and more variable in vehicle-treated CAG140 mice. Thus, the HD mutation has a strong effect on the encoding of long-term memory in many, but not all, CAG140 mice at 16 weeks of age. It will be interesting to determine whether the percentage of mice affected increases with disease progression because, as noted, LTP impairments worsen with age. Ampakine treatment again normalized the behavior of the mutants: CX929-treated CAG140 and WT mice showed the same relative increase in the amount of time spent with the novel object and these values were substantially greater than those seen in the vehicletreated mutants. These results indicate that ampakine treatment offsets memory encoding impairments in CAG140 mice, because it did not change the extent to which the mutants explored the objects and environmental cues on days 2 and 3. Novel object recognition depends, in part, on hippocampus (26, 27) and is blocked by manipulations that disrupt LTP (28) . Therefore, the most straightforward explanation of these findings is that the rescue of hippocampal LTP that accompanies BDNF upregulation in CAG140 mice, restores the synaptic plasticity needed for the encoding of information about environmental cues (i.e., familiarization), and thereby for recognizing novelty.
There currently are no treatments for cognitive problems associated with HD and indeed previous studies using BDNFbased treatments in animal models of the disease have not evaluated effects on cognition. The BDNF strategy tested here could, in principle, be implemented with other manipulations (e.g., antidepressants) that increase expression of the neurotrophin, but side-effect profiles would likely preclude extended clinical applications. However, the drug protocols used in the present studies did not produce generalized changes in behavior, and ampakines, at doses that positively affect learning, are not reported to have noticeable side effects in primates (29) including humans (30) . Moreover, the short half-life of the tested ampakine is a very positive feature with regard to long-term usage. It is also of interest in this regard that the multiple families of ampakines now under development (31) provide a wide assortment of structurally distinct candidates for an HD therapeutic. Whether the elevated BDNF levels produced by the compounds affect the development of HD-related neuropathology is a critical issue for future research.
Materials and Methods
All procedures were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and protocols approved by the Institutional Animal Care and Use Committee of the University of California at Irvine.
Mice and Genotyping. Male homozygous CAG140 mice at 8 and 16 weeks of age were used. These mice were of a mixed C57BL/6J ϫ 129/Sv background (N2-N3 on C57BL/6J) and have a chimeric mouse-human exon 1 with Ϸ140 repeats of the trinucleotide CAG inserted into the huntingtin gene (32) . Homozygous WT littermates from the heterozygous breeding pairs were mated for at least 3 generations and used as controls. Genotypes and CAG repeat numbers were determined by Laragen. Mice used in this study had 125 Ϯ 3 and 134 Ϯ 2 (mean Ϯ SD) CAG repeats for the 2 alleles, respectively. Ampakine Treatment. Mice for electrophysiological and behavioral experiments were divided into 3 groups: WT ϩ vehicle, CAG140 ϩ vehicle, and CAG140 ϩ ampakine. They received 2 injections (i.p.) per day (9 AM and 4 PM) for 8 days; the first 4 days were vehicle [10% cyclodextrin (HPCD) in 0.45% saline] injections, for habituation, followed by 4 days of either HPCD or ampakine (CX929 at 5 mg/kg) injections (see Tables S1 and S2 ). The regimen and dosage was selected on the basis of unpublished physiological studies on concentrations needed to increase monosynaptic responses in hippocampus and published work showing that spaced injections with 5 mg/kg increases BDNF protein content without altering exploratory behavior (25) . After each injection, mice used for physiology were placed in an enriched open-field environment with cage mates for 20 min. Past work has shown that behavioral activity increases BDNF levels; we have found it enhances BDNF up-regulation with ampakine treatment (see ref. 25 for discussion). Those studies further determined that BDNF protein levels are increased after the first injection day and remain comparably elevated 18 h after injections on days 2, 3, and 4.
Electrophysiology and in Situ Labeling of F-Actin. Hippocampal slices from 8-and 16-week-old CAG140 and age-matched WT mice were tested in parallel in interface chambers according to standard methods (11) . fEPSPs were elicited by stimulation of the Schaffer-commissural projections and recorded from proximal stratum radiatum of CA1b; LTP was induced by a 10-burst TBS train (11) . Synaptic responses were normalized to a 10-min pre-TBS baseline. The N values in the figures represent the number of slices; 1 or 2 slices were evaluated for each mouse. Means and variances represent pooled values for all slices, as is typical for LTP experiments (e.g., refs. 33 and 34). F-actin was labeled before electrophysiological recording by using standard protocols (20) 
(SI Text).
Human recombinant BDNF (2 nM; Chemicon) or heat-inactivated BDNF (boiled 5 min) in artificial cerebrospinal fluid was delivered to slices via a reperfusion pump system at 1 mL/min; infusion was initiated 1-2 h before recording, as described (11) . The selected concentration (2 nM) partially activates actin signaling in adult slices (15) with little, if any, effect on baseline synaptic physiology (20) .
Western Blot Analysis. Whole hippocampal homogenates were separated by 15% PAGE and processed for Western blot analysis using rabbit anti-BDNF (1:1,000; SC546; Santa Cruz) followed by ECL Plus (Amersham) and quantified (11) . The BDNF antisera detects distinct pro BDNF and mBDNF bands as described (11, 35, 36) . Recombinant human BDNF (Chemicon) was added as positive control. Blots were stripped and reprobed with anti-tubulin and anti-actin (both 1:4,000) to control for loading variations.
Unsupervised Learning Paradigm. Mice (16 weeks old) used for behavior experiments received injections as described above (see ''Ampakine treatment'') starting 8 days before testing with the exceptions that they were placed in their home cage after injection and their vehicle or drug treatment continued through the 4 days of behavior testing (Table S2) . Testing was conducted at least 1 h into the dark phase of the light cycle and 1-2 h after the morning injection.
Mice were tested for 60 min over 4 consecutive days in a complex open-field environment, used previously (24) , that lacked objects/compartments on day 1. On testing days 2 and 3, an enclosed dark compartment and 2 identical objects were added to the arena; one object was replaced with a novel object on testing day 4 (Fig. S3) . Preference tests conducted on a separate group of WT mice (n ϭ 7) showed that mice explored each object equally. Defined regions of the testing environment were: refuge; porch (at the entry of the homebox); objects 1 and 2; corners 1-3 (4 is the porch); and open field (light compartment not containing other areas). Behavior was recorded via an overhead CCD camera (Panasonic WV-BP334). The center point of the animal was tracked (15 Hz) and images were analyzed with EthoVision XT video
